1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P992055
    Anti-ITGB1 Antibody
    Inhibitor
    Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma.
    Anti-ITGB1 Antibody
  • HY-10308
    Lefradafiban
    Antagonist 98.92%
    Lefradafiban is an orally active glycoprotein IIb/IIIa receptor antagonist. Lefradafiban can be metabolized to its active form, Fradafiban, a non-peptide GP IIb/IIIa receptor antagonist.
    Lefradafiban
  • HY-16141R
    Cilengitide (Standard)
    Antagonist
    Cilengitide (Standard) is the analytical standard of Cilengitide. This product is intended for research and analytical applications. Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
    Cilengitide (Standard)
  • HY-B0932R
    Levocarnitine propionate hydrochloride (Standard)
    Inhibitor
    Adrenalone (hydrochloride) (Standard) is the analytical standard of Adrenalone (hydrochloride). This product is intended for research and analytical applications. Adrenalone hydrochloride is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone hydrochloride is an inhibitor of dopamine β oxidase. Adrenalone hydrochloride is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM.
    Levocarnitine propionate hydrochloride (Standard)
  • HY-145728A
    Alicaforsen sodium
    Inhibitor
    Alicaforsen (ISIS-2302) sodium is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen sodium hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen sodium is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease.
    Alicaforsen sodium
  • HY-17369A
    Tirofiban hydrochloride
    Antagonist
    Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
    Tirofiban hydrochloride
  • HY-145728D
    Alicaforsen sodium scrambled negative control
    Inhibitor
    Alicaforsen sodium scrambled negative control is the sequence scrambled negative control of Alicaforsen sodium.
    Alicaforsen sodium scrambled negative control
  • HY-119350C
    Zalunfiban acetate
    Antagonist
    Zalunfiban (RUC-4) acetate is a potent, selective platelet αIIbβ3antagonist (IC50=45 nM). Zalunfiban acetate can be used for the research of myocardial infarction (MI).
    Zalunfiban acetate
  • HY-P5929
    VnP-16
    VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation.
    VnP-16
  • HY-125668
    Ro 43-5054
    Ro 43-5054 is a platelet glycoprotein IIb-IIIa receptor antagonist. Ro 43-5054 can be used in the research of early reocclusion after thrombolytic therapy.
    Ro 43-5054
  • HY-P0038
    MK-852
    Antagonist
    MK-852 (L-367073) is an effective GPIIb/IIIa receptor antagonist. MK-852 can significantly inhibit the binding of fibrinogen to platelets in vitro. MK-852can be used for the study of thrombosis.
    MK-852
  • HY-P1613
    Cyclo(Arg-Gly-Asp-D-Phe-Val)
    Inhibitor
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia.
    Cyclo(Arg-Gly-Asp-D-Phe-Val)
  • HY-P992115
    Furtisetabart
    Inhibitor
    Furtisetabart is a humanized monoclonal antibody targeting CD147 with anti-tumor activity. Furtisetabart is of the human IgG4κ antibody subtype, and the recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Furtisetabart
  • HY-172495
    DSPE-PEG3000-iRGD
    DSPE-PEG3000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG3000-iRGD can be used for drug delivery.
    DSPE-PEG3000-iRGD
  • HY-P10984
    FNIII14
    Inhibitor
    FNIII14 is derived from the 14th fibronectin (FN) type III-like (FN-III) repeat of FN molecule. FNIII14 is capable of inhibiting cell adhesion to the extracellular matrix (ECM). FNIII14 induces a conformational change in β1-integrin from the active to the inactive form, and blocks integrin-mediated signaling. FNIII14 has anti-fibrotic, anti-cancer effect. FNIII14 can be used for research of metabolic diseases, organ fibrosis, and malignant tumors.
    FNIII14
  • HY-186079
    Deethyl-emvistegrast
    Inhibitor
    Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. Deethyl-emvistegrast is the hydrolytic product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways. Deethyl-emvistegrast can be used in research related to inflammatory bowel disease (Crohn's disease and ulcerative colitis).
    Deethyl-emvistegrast
  • HY-P991254
    VPI-2690B
    Inhibitor
    VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research.
    VPI-2690B
  • HY-137561A
    Bexotegrast hydrochloride
    Inhibitor
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts.
    Bexotegrast hydrochloride
  • HY-P991851
    Anti-CD11c Antibody (3.9)
    Inhibitor
    Anti-CD11c Antibody (3.9) recognizes human CD11c. Anti-CD11c Antibody (3.9) blocks CD11c on human peripheral blood mononuclear cell-derived dendritic cells (MoDCs). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD11c Antibody (3.9)
  • HY-P11649
    NYLTHRQ
    Inhibitor
    NYLTHRQ is a peptide. NYLTHRQ specifically blocks the interaction between sVEGFR1-i13 and β1 integrin, and inhibits the activation of VEGFR1 and VEGFR2. NYLTHRQ inhibits cancer cell proliferation. NYLTHRQ can be used in the research of tumors such as lung squamous cell carcinoma.
    NYLTHRQ
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.